Redox-regulated processes are important elements in various cellular functions. Reducing agents, such as Nacetyl-L-cysteine (NAC), are known to regulate signal transduction and cell growth through their radical scavenging action. However, recent studies have shown that reactive oxygen species are not always involved in ligand-stimulated intracellular signaling. Here, we report a novel mechanism by which NAC blocks platelet-derived growth factor (PDGF)-induced signaling pathways in hepatic stellate cells, a fibrogenic player in the liver. Unlike in vascular smooth muscle cells, we found that reducing agents, including NAC, triggered extracellular proteolysis of PDGF receptor-␤, leading to desensitization of hepatic stellate cells toward PDGF-BB. This effect was mediated by secreted mature cathepsin B. In addition, type II transforming growth factor-␤ receptor was also down-regulated. Furthermore, these events seemed to cause a dramatic improvement of rat liver fibrosis. These results indicated that redox processes impact the cell's response to growth factors by regulating the turnover of growth factor receptors and that "redox therapy" is promising for fibrosis-related disease.
Reactive oxygen species are known to activate intracellular signal molecules (1) . Extracellular signal-regulated kinase is one of the reactive oxygen species-responsive serine/threonine kinases (2) . A recent study showed that hydrogen peroxide (H 2 O 2 ) directly attacks G␣ o and G␣ i to activate extracellular signal-regulated kinase in rat neonatal cardiomyocytes (3) . In addition to the direct activation of signal molecules, H 2 O 2 was also reported to contribute to the phosphorylation of mitogenactivated protein kinase in vascular smooth muscle cells (VSMC) 1 under the stimulation of the platelet-derived growth factor (PDGF) (4) . However, recent studies have forced reconsideration of this hypothesis. In HepG2 cells, PDGF receptor (PDGFR) was autophosphorylated independently of H 2 O 2 production (5) . In epithelial cells, interleukin-1␤ activated NF-B without H 2 O 2 production (6). These evidences confirmed that reactive oxygen species are not always involved in ligandinduced signaling pathways. The hepatic stellate cell (HSC), a liver-specific pericyte, plays a central role in liver fibrogenesis (7) . When undergoing activation, the HSC proliferates and generates a large amount of extracellular matrix materials including fibril-forming collagens, fibronectin, and proteoglycans, resulting in septum formation in chronically damaged liver. Because recent studies have confirmed that PDGF is the most potent mitogen for HSC (8) , regulation of PDGF-stimulated HSC proliferation would serve as a therapeutic target for liver fibrosis. Here we show that reducing agents, including N-acetyl-L-cysteine (NAC), have the potential to disturb PDGF-dependent signal transductions and DNA synthesis in HSC. Molecular analysis revealed that NAC triggered extracellular proteolysis of PDGFR-␤ through the activation of a thiol-protease, cathepsin B, independently of its H 2 O 2 scavenging action.
EXPERIMENTAL PROCEDURES
Materials-Collagenase and thioacetamide (TAA) were purchased from Wako Pure Chemical Co. (Osaka, Japan). Pronase E was purchased from Merck. PDGF-BB was purchased from R & D systems (Minneapolis, MN). The polyclonal antibodies against PDGFR-␣ and PDGFR-␤, type I transforming growth factor-␤ receptor (TGF-␤RI), and TGF-␤RII were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). The monoclonal antibodies against cathepsin B and phosphotyrosine were purchased from Upstate Biotechnology, Inc. (Lake Placid, NY). The polyclonal antibodies against phosphoextracellular signal-regulated kinase and phospho-Akt were purchased from New England Biolabs (Beverly, MA). The monoclonal antibody against smooth muscle ␣-actin (␣-SMA), desmin, vimentin, and glial fibrillary acidic protein were purchased from DAKO A/S (Glostrup, Denmark). * This work was supported by Grants-in-aid for Scientific Research (from the Ministry of Education, Science, Sports and Culture, Japan) 10470240 (to Y. S.), 11557084 (to Y. S.), and 12470238 (to Y. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
‡ To whom correspondence should be addressed: Dept. of Gastroenterological Surgery, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8397, Japan. Tel.: 81-75-751-3242; Fax: 81-75-751-4263; E-mail: yokuyama@f8.dion.ne.jp. 1 The abbreviations used are: VSMC, vascular smooth muscle cell(s); NAC, N-acetyl-L-cysteine; PDGF, platelet-derived growth factor; PDGFR, platelet-derived growth factor receptor; HSC, hepatic stellate cell; BSO, L-buthionine-(S,R)-sulfoximine; E64, L-3-carboxy-2,3-trans-epoxypropionyl-(4-guanidine)butane; E64-c,
2-ME, 2-mercaptoethanol; TGF, transforming growth factor; TGF-␤R, transforming growth factor-␤ receptor; ␣-SMA, smooth muscle ␣-actin; TAA, thioacetamide; IP, immunoprecipitation; WB, Western blot; MAP, mitogen-activated protein; 32 P]dCTP, and 125 I-PDGF-BB were purchased from Amersham Pharmacia Biotech. E64, E64-c, E64-d, CA074, and pepstatin A were purchased from the Peptide Institute (Osaka, Japan). These drugs were dissolved in Me 2 SO before use, and, throughout the experiments, the final concentration of Me 2 SO in cell culture medium was kept at 0.5% including control cultures. Unless specifically indicated, all other reagents were purchased from Sigma.
Animals-Pathogen-free male Wistar rats were obtained from SLC (Shizuoka, Japan). Animals were housed at a constant temperature and supplied with laboratory chow and water ad libitum. The protocol of experiments was approved by the Animal Research Committee of Osaka City University (Guide for Animal Experiments, Osaka City University).
Isolation of Rat HSC and VSMC-We isolated HSC from Wistar rat livers using Pronase E and the collagenase digestion method as previously described (9) . Cell purity was around 95% as assessed by a typical starlike configuration and by detecting vitamin A autofluorescence. Cells were cultured on plastic dishes in Dulbecco's modified Eagle's medium (Life Technologies, Inc.) supplemented with 10% fetal calf serum (Life Technologies). We changed the culture medium every 2 days.
We isolated VSMC from Wistar rat thoracic aorta by subcultured explants method as previously described (10) . Cells were cultured on plastic dishes in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. Passaged cells were used in an in vitro assay.
In all experiments, we incubated HSC or VSMC in serum-free Dulbecco's modified Eagle's medium for 24 h before the addition of test agents.
[ 3 H]Thymidine Incorporation Assay-We treated confluent HSC with NAC for 24 h, followed by treatment with PDGF-BB (20 ng/ml) for another 24 h. Cells were pulse-labeled with 1.0 Ci/ml [ 3 H]thymidine during the last 6 h. Incorporated radioactivity was counted as previously described (11) .
Immunoprecipitation-We lysed HSC cultured in a 60-mm dish (FALCON 3002; Becton Dickinson, Flanklin Lakes, NJ) by 500 l of radioimmune precipitation buffer (10 mM Tris-HCl, pH 7.4, 1% IGEPAL CA-630, 0.1% SDS, 0.1% sodium deoxycholate). The lysates (500 g) were incubated with 2 g of antibody against PDGFR-␤ at 4°C for 24 h, followed by incubation with 20 l of protein G plus agarose (Santa Cruz Biotechnology) at 4°C for 1 h.
Western Blotting-We homogenized HSC treated with EDTA (Wako), 1,10-phenanthroline, phenylmethylsulfonyl fluoride, leupeptin, chymostatin, E64, E64-c, E64-d, CA074, and pepstatin A in 1ϫ SDS sample buffer (100 l/35-mm dish) (62.5 mM Tris-HCl, pH 6.8, 10% glycerol, 2% SDS, 5% 2-␤-mercaptoethanol, 1 mM Na 3 VO 4 ). After heat denaturation, the samples (10 g of protein) were subjected to SDS-polyacrylamide gel electrophoresis (6 -12%) and then transferred onto an Immobilon P membrane (Millipore Corp., Bedford, MA). The membranes were subsequently treated with monoclonal antibody against either ␣-SMA, PDGFR-␤, TGF-␤R, phosphotyrosine (4G10), phopsho-Akt, or phospho-MAP kinase. Immunoreactive bands were visualized on Eastman Kodak Co. XAR5 films, using ECL detection reagent (Amersham Pharmacia Biotech).
Metabolic Labeling-After treatment with Dulbecco's modified Eagle's medium lacking methionine (Life Technologies), we incubated HSC with 0.1 mCi of [ 35 S]methionine for 24 h at 37°C. After removal of the radioactive medium, they were incubated with NAC for the following 24 h at 37°C. After incubation, HSC were washed twice with cold phosphate-buffered saline. HSC were lysed by scraping into radioimmune precipitation buffer and prepared for immunoprecipitation. Immunoprecipitations were performed as described above using anti-PDGFR-␤ antibody followed by adsorption to protein G plus agarose. SDS-polyacrylamide gel electrophoresis was carried out in 6% gels. Gels were dried and exposed to Kodak XAR5 x-ray film at Ϫ80°C for 1 week.
125
I-PDGF-BB Binding Experiment-We measured the binding capacity of 125 I-PDGF-BB to HSC cultured in 35-mm dishes as previously described (12) . Briefly, HSC were incubated on ice for 2 h with 1 ng/ml 125 I-PDGF-BB in the presence or absence of 400 ng/ml of unlabeled PDGF-BB. After incubation, radioactivity in the lysate was determined in a ␥-counter (Aloka Auto well ␥ system ARC-2000, Tokyo, Japan). The radioactivity in the presence of unlabeled PDGF-BB was subtracted as nonspecific binding.
Quantification of mRNA by Northern Blotting-We extracted total RNA from the cells using Isogen (Nippon Gene, Tokyo, Japan) as described previously (17) . Total RNA (20 g) was separated on a 1% agarose gel (Nippon Gene) and transferred onto a nylon membrane (Hybond-N ϩ ; Amersham Pharmacia Biotech). After prehybridization, the membrane was incubated in the buffer supplemented with polymerase chain reaction-amplified double-stranded cDNAs, which were labeled with [␣-32 P]dCTP using a Rediprime DNA Labeling System (Amersham Pharmacia Biotech), followed by autoradiography on a Kodak XAR5 x-ray film. The following primers were used: PDGFR-␤, 5Ј-GATGTCACTGAGACGACGAT-3Ј (forward) and 3Ј-CCTCAAACAC-CACCTGCAAC-5Ј (reverse); glyceraldehyde-3-phosphate dehydrogenase, 5Ј-ACCACAGTCCATGCCATCAC-3Ј (forward) and 3Ј-TCCACCA-CCCTGTTGCTGTA-5Ј (reverse). Identification of amplified DNAs was confirmed by sequencing.
In Vitro Proteolysis of PDGFR-␤ Protein-We incubated the immunoprecipitated PDGFR-␤ protein for 1 h at 37°C with NAC (20 mM) in the presence or absence of either 0.05 unit of cathepsin B, 0.05 unit of cathepsin D, or 1 mM E64. Then the samples were subjected to 6% SDS-polyacrylamide gel electrophoresis, followed by Western blot. We confirmed the immunoprecipitated band at 180 kDa as rat PDGFR-␤ by amino acid sequencing of the proteins using a Q-TOF mass spectrometer (Micromass, Manchester, United Kingdom).
TAA-induced Liver Fibrosis Model-We injected TAA (50 mg/body) twice a week intraperitoneally into rats (n ϭ 15). We administered NAC (100 mg/body) simultaneously either intraperitoneally (n ϭ 5) or orally (n ϭ 5) every day for 6 weeks. In another model, we injected TAA for 9 weeks (n ϭ 15), and NAC (100 mg/body) was administered either intraperitoneally (n ϭ 5) or orally (n ϭ 5) during the last 3 weeks. One day after the final injection, rats were anesthetized by diethylether, and the peritoneal cavity was opened. The liver was perfused with phosphate-buffered saline via the portal vein at a flow rate of 10 ml/min until the blood was completely removed from the whole liver lobules. Subsequently, the liver was removed. A part of the liver was fixed in 10% formaldehyde and used for histologic examination. The remaining part was quickly frozen in liquid nitrogen and stored at Ϫ80°C until use.
Bile Duct Ligation-induced Liver Fibrosis-We laparotomized rats (n ϭ 10) and ligated the common bile ducts at the two different sites. We administered NAC (100 mg/body) intraperitoneally every day for 2 weeks (n ϭ 5).
Mallory Azan Staining and Morphometric Analysis of Fibrotic
Area-We stained the paraffin-embedded sections (4-m thickness) with Mallory azan, followed by morphometric analysis of fibrotic area using Mac SCOPE version 2.5 (MITANI Corp.) and Photgrab-2500 for Macintosh FUJIX SH-25/M (FUJIFILM, Tokyo, Japan). Five nonoverlapping areas were evaluated in each group.
Immunohistochemistry-In immunohistochemistry, tissue sections were treated with 1% hydrogen peroxide, 0.1% proteinase K, and 1% Triton X-100. They were reacted with 1:50-diluted mouse monoclonal antibody against ␣-SMA overnight at 4°C, followed by reaction with 1:200-diluted biotin-conjugated rabbit anti-mouse IgG F(abЈ) 2 for 1 h at room temperature.
Statistical Analysis-Data presented as bar graphs are the means Ϯ S.D. of three independent experiments except for in vivo analysis of five independent experiments. Luminograms and autoradiograms are representative of at least three experiments. Statistical analysis was performed by Student's t test (p Ͻ 0.05 was considered significant).
RESULTS
Treatment of HSC with NAC inhibited PDGF-BB-dependent DNA synthesis in a dose-dependent manner (Fig. 1A) . NAC impeded the phosphorylation of tyrosine residue of PDGFR-␤ and the activation of both MAP kinase and Akt dose-dependently under PDGF-BB stimulation (Fig. 1, B-D) . Notably, NAC down-regulated the protein level of PDGFR-␤ dose-dependently (Fig. 1E) .
125 I-PDGF-BB binding experiments showed that pretreatment with NAC for 24 h decreased the specific binding of PDGF-BB to HSC (Fig. 1F) . These results indicate that NAC blocked PDGF-dependent signaling pathways and DNA synthesis in HSC through the down-regulation of PDGFR-␤ protein.
NAC triggered down-regulation of PDGFR-␤ protein in a dose-and time-dependent manner (Fig. 2, A and B) . Since removal of NAC restored PDGFR-␤, this effect of NAC was not derived from its cytotoxic action (Fig. 2C) . BSO, an inhibitor for GSH production, did not restore the down-regulation of PDGFR-␤ (Fig. 2D ). This result indicated that GSH endogenously produced is not involved in this effect of NAC. Northern blot analysis showed that NAC had no effect on the expression of PDGFR-␤ mRNA (Fig. 2E) . Metabolic labeling experiments revealed that NAC reduced de novo synthesized PDGFR-␤ (Fig. 2F) . These results indicated that this effect of NAC was presumably due to accelerating degradation of PDGFR-␤ that had already been synthesized. To clarify the mechanism by which NAC down-regulates PDGFR-␤ protein in HSC, we tested whether protease inhibitors affected NAC-induced degradation of PDGFR-␤ protein.
EDTA and 1,10-phenanthroline are inhibitors of matrix metalloprotease; phenylmethylsulfonyl fluoride inhibits a serine protease; chymostatin inhibits chymotrypsin, papain, and cathepsin A, B, and D; leupeptin inhibits trypsin, plasmin, papain, and cathepsin B; E64 inhibits thiol proteases including cathepsin B, H, and L and calpain; CA074 inhibits cathepsin B; and pepstatin A inhibits cathepsin D. Among these protease inhibitors, chymostatin, leupeptin, E64, CA074, and pepstatin A hampered NAC-induced down-regulation of PDGFR-␤ (Fig.  3A) . Proteasome inhibitors such as MG115 and PSI failed to affect the degradation of PDGFR-␤ by NAC. These results indicate that down-regulation of PDGFR-␤ protein expression is mediated through its degradation by cathepsin B and/or cathepsin D.
Next, we determined whether cathepsin B or cathepsin D could degrade PDGFR-␤ protein using in vitro degradation assays. Neither NAC alone nor cathepsin B alone had any effect on PDGFR-␤ protein (Fig. 3B) . However, cathepsin B in combination with NAC induced degradation of PDGFR-␤ protein in an E64-inhibitable manner. In contrast, cathepsin D had no effect on PDGFR-␤ protein level with or without NAC. These results indicate that cathepsin B is responsible for the degradation of PDGFR-␤ and that NAC is required for the activation of cathepsin B.
Western blot analysis showed that reducing agents, such as L-cysteine, GSH, 2-mercaptoethanol (2-ME), and dithiothreitol, down-regulated PDGFR-␤, while L-cystine and GSSG failed to affect the PDGFR-␤ level (Fig. 3C) . Trolox (a water-soluble derivative of vitamin E) had no effect either. These results Then the samples were subjected to SDSpolyacrylamide gel electrophoresis in 6% gel, followed by Western blot. C, effect of reducing agents, such as L-cysteine, GSH, 2-ME, and dithiothreitol (DTT), and nonreducing agents, such as L-cystine and GSSG, and Trolox, a water-soluble vitamin E, on the expression of PDGFR-␤. D, effect of membrane-permeable and -impermeable thiol protease inhibitors on the effect of NAC. E, determination of the presence of cathepsin B in the culture medium of HSC and VSMC by Western blot. Confluent HSC or VSMC were deprived of serum in 100-mm dishes and then cultured for 24 h. The culture medium (1 ml) was centrifuged to remove the debris, followed by concentration into 10 l using Microcon YM-100 (Millipore).
indicate that reducing agents play an essential role in the enhancement of the catalytic activity of cathepsin B, which is consistent with the general character of thiol proteases (13) .
Next, we tested the site where cathepsin B degraded PDGFR-␤. E64-c is a membrane-impermeable derivative of E64 (14) . E64-d is a membrane-permeable derivative of E64 (15) . CA074 is a membrane-impermeable derivative (16) . Both E64-c and CA074 were able to restore the PDGFR-␤ protein similarly to E64-d (Fig. 3D) . These results indicate that PDGFR-␤ might be degraded extracellularly by cathepsin B in the presence of NAC. In fact, mature cathepsin B as well as procathepsin B was present in the culture medium of activated HSC (Fig. 3E) . This is consistent with the report by Kristensen et al. (17) showing that proteome analysis detected cathepsin B in the culture supernatant of HSC.
In sharp contrast to HSC, VSMC secreted procathepsin B, but not mature cathepsin B, into the culture medium (Fig.  3E) . Here, we assumed that NAC might have no effect on the expression of PDGFR-␤ in VSMC. As expected, NAC failed to affect both the protein level of PDGFR-␤ and tyrosine phosphorylation of PDGFR-␤ under PDGF-BB stimulation in VSMC (Fig. 4, A and B) . Accordingly, NAC had no effect on the phosphorylation of MAP kinase and Akt under PDGF-BB stimulation in VSMC (Fig. 4, C and D) . However, NAC blocked the DNA synthesis of VSMC under PDGF-BB stimulation in a dose-dependent manner, as previously reported (Fig. 4E) (4) . These results indicate that NAC may block some signal molecules except for PDGFR-␤, MAP kinase, and Akt in VSMC.
Next, we examined whether the above mentioned effect of NAC was specific for PDGFR-␤. NAC was also found to downregulate the expression of TGF-␤RII (Fig. 5) . In contrast, NAC had no effect on the expression of other receptors, such as PDGFR-␣ and TGF-␤RI. NAC also failed to affect the level of cytoskeletous proteins, such as ␣-SMA, desmin, vimentin, and glial fibrillary acidic protein (Fig. 5) .
The above mentioned results indicated that NAC may suppress liver fibrosis by inhibiting HSC proliferation through inducing unresponsiveness to growth factors, such as PDGF-BB and TGF-␤. To test this hypothesis, we prepared two different liver fibrosis models. First, we examined whether NAC could suppress thioacetamide (TAA)-induced liver fibrosis. Mallory azan staining revealed that fibrosis was well developed in the liver of rats treated with TAA for 6 weeks (fibrotic area 8.16 Ϯ 1.24%) (Fig. 6, A and K) . NAC treatment either intraperitoneally or orally suppressed fibrosis of the liver (1.79 Ϯ 0.51 or 2.51 Ϯ 0.90%, p Ͻ 0.01) (Fig. 6, B, C, and  K) . Immunostaining of ␣-SMA, a marker of myofibroblast and activated HSC, showed that, while ␣-SMA-positive cells were numerous in and around fibrotic septum of TAA-treated livers (Fig. 6G) , administration of NAC suppressed the increase of ␣-SMA-positive cells (Fig. 6H ). This result indicated that NAC inhibited the proliferation of activated HSC also in in vivo fibrosis models. To further test whether NAC had the potential to restore the liver fibrosis that had already been developed, we started NAC treatment 6 weeks after TAA administration and excised liver tissues for histologic evaluation 3 weeks later. Liver fibrosis progressed with thick bundles of elastic fibers after 9-week administration of TAA (12.44 Ϯ 1.74%) (Fig. 6, D  and K) . However, NAC treatment during the last 3 weeks either intraperitoneally or orally restored the fibrotic liver tissue to almost physiological architecture (1.79 Ϯ 0.51 or 2.51 Ϯ 0.90%, p Ͻ 0.01) (Fig. 6, E, F, and K) .
Next, we examined the effect of NAC on the bile duct ligation model. Bile duct ligation for 2 weeks induced cholestasis, periductular hepatocyte necrosis with leukocyte accumulation, and fibrosis around the portal area (3.50 Ϯ 2.06%) (Fig. 6, I and K) . When we administered NAC on a daily basis, the deposition of extracellular matrix was much less than that in nontreated rats (1.45 Ϯ 1.49%, p Ͻ 0.05) (Fig. 6, J and K) .
Finally, we examined whether NAC could down-regulate growth factor receptors in rat livers. Western blot analysis revealed that neither PDGFR-␤ protein nor TGF-␤RII protein was detectable in liver tissues of rats treated with TAA and NAC (Fig. 6L) . In contrast, the protein level of PDGFR-␣, TGF-␤RI, and ␣-SMA showed limited suppression by NAC administration. These results indicate that NAC has a potential to induce degradation of both PDGFR-␤ and TGF-␤RII in vivo.
DISCUSSION
Redox regulation by intrinsic reducing suppliers, including GSH and thioredoxin, is essential to maintain intact cellular functions against oxidative stress in many mammalian cells (18) . Both GSH and thioredoxin regulate cell growth and death by modulating superoxide-sensitive transcription factors, such as AP-1 and NF-B (19) . Likewise, extrinsic reducing suppliers, such as NAC, are known to regulate cell growth by increasing intracellular GSH production. NAC has been clinically utilized for acute respiratory distress syndrome, cancer, chronic bronchitis, heart disease, heavy metal poisoning, human immunodeficiency virus infection, and acetaminophen-induced liver injury (20) .
Our current study provides a new insight into the pathophysiological role of redox processes. We found that the extracellular reduced condition may be an important factor for the regulation of growth factor-stimulated cellular response through the degradation of membrane receptors assisted with secreted cathepsin B. However, such a phenomenon was observed after the long term exposure of HSC to NAC. In in vitro culture, NAC at 20 mM required 24 h for inducing complete degradation of PDGFR-␤. In contrast, we found that the exposure of HSC to NAC for 30 min could also inhibit PDGF-dependent signaling without any change of PDGFR-␤ protein level (data not shown). Moreover, although E64 completely restored the expression of PDGFR-␤ at the protein level, E64-induced recovery of PDGFdependent DNA synthesis and signaling was limited (data not shown). These results suggest that NAC may additionally modify the PDGF-induced signaling cascade by some unknown mechanism other than proteolytic action.
Sundaresan et al. (4) Cathepsin B belongs to a family of thiol proteases and localizes in lysosome. Cathepsin B has been reported to digest intracellularly antigens, immunoglobulin heavy chain, insulin A and B chain, glucagon, actin, myosin heavy chain, albumin, collagen, fibronectin, proteoglycans, fibrinogen, proplasminogen activator, and trypsinogen (13) . However, some studies reported that malignant cells, fibroblasts, and osteoblasts secrete cathepsin B into the extracellular space (21) . These cells are reported to secrete procathepsin B but not mature cathepsin B. In contrast, we detected the presence of mature-type cathepsin B in the culture medium of HSC. Some studies showed that cathepsin D is necessary for the processing of procathepsin B to mature cathepsin B (22) . Since pepstatin A impeded PDGFR-␤ degradation (Fig. 3A) , it seems that cathepsin D is also involved in the activation of cathepsin B, leading to the degradation of PDGFR-␤ by NAC in HSC.
Although the protective and antioxidative effect of NAC on hepatocytes should be taken into account, we showed that NAC down-regulated the expression of both PDGFR-␤ and TGF-␤RII also in in vivo liver fibrosis models (23) . TGF-␤ is the most potent fibrogenic factor for HSC (24) . Some studies reported that inhibition of TGF-␤ action resulted in the suppression of 
FIG. 6. Effect of NAC on rat liver fibrosis models.
A-H, TAA was administered to induce liver fibrosis. After TAA administration, rats were sacrificed. The liver was perfused with phosphate-buffered saline, fixed in 10% formaldehyde, and used for histologic examination. A-C, TAA was administered at 50 mg/body for 6 weeks (A, n ϭ 5). NAC was simultaneously administered intraperitoneally (B, n ϭ 5) or orally (C, n ϭ 5) with TAA for 6 weeks. D-F, TAA and NAC (100 mg/body) were administered for 3 weeks after liver fibrosis was completed by TAA preadministration for 6 weeks. TAA alone was administered for 9 weeks (D, n ϭ 5). Rats were treated with NAC intraperitoneally (E, n ϭ 5) or orally (F, n ϭ 5) with simultaneous administration of TAA during the last 3 weeks. G and H, immunostaining of ␣-SMA on the livers treated by TAA (G, n ϭ 5) and TAA plus NAC (H, n ϭ 5) for 6 weeks. I and J, bile duct ligation was performed in rats to induce liver fibrosis. After 2 weeks, rats were sacrificed. The liver was perfused with phosphatebuffered saline, fixed in 10% formaldehyde, and used for histologic examination. Rats were treated with NAC (J, n ϭ 5). K, percentage of fibrotic area was determined by morphometric analysis using samples in (A-F, I, and J). Closed bar, TAA only; dotted bar, TAA plus NAC (intraperitoneally); open bar, TAA plus NAC (orally). Values are means Ϯ S.D. determined from five individual animals (*, p Ͻ 0.01; #, p Ͻ 0.05). L, effect of NAC on the expression of the membrane receptors, such as PDGFR-␣, PDGFR-␤, TGF-␤RI, and TGF-␤RII, and the cytoskeletous protein, ␣-SMA, in rat liver tissues was determined by Western blot. One hundred g of liver tissue samples was lysed in 1ϫ SDS sample buffer (2 ml), followed by Western blot.
liver fibrosis (25) . Hence, we assumed that cathepsin B-mediated proteolysis of TGF-␤RII might contribute to the suppression of liver fibrosis in the in vivo model. More surprisingly, NAC has the potential to reverse established liver fibrosis (Fig.  6, D-F) . In this context, we assume that NAC may induce cathepsin B-mediated direct degradation of extracellular matrix. In fact, some studies showed that cathepsin B degraded extracellular matrix (26) . Leto et al. (27) reported that in human serum the concentration of cathepsin B is significantly higher in patients with liver cirrhosis than in normal volunteers, indicating a clinical benefit of NAC for patients with liver fibrosis.
